摘要
目的探讨阿托伐他汀对轻度认知功能障碍(MCI)和阿尔茨海默病(AD)患者IL-1β、IL-6及TNF-α水平的影响。方法 60例MCI患者(MCI组)随机均分为MCI对照组和MCI治疗组,60例AD患者(AD组)随机均分为AD对照组和AD治疗组。对照组均采用基础药物治疗;而治疗组均在对照组的基础上加用阿托伐他汀片20mg。比较各组患者治疗前后脑脊液和血液中IL-1β、IL-6及TNF-α水平的变化,并分析IL-1β、IL-6和TNF-α间的关系。结果治疗后6个月,四组IL-1β、IL-6和TNF-α水平均低于治疗前(P<0.05),两个治疗组的IL-1β、IL-6和TNF-α水平均低于对照组(P<0.05),且AD治疗组IL-1β、IL-6和TNF-α水平低于MCI治疗组(P<0.05)。MCI组IL-1β、IL-6和TNF-α之间均无明显相关性(P>0.05),而AD组IL-1β与TNF-α呈正相关(r=0.427,P<0.05)。结论阿托伐他汀能降低MCI和AD患者IL-1β、IL-6及TNF-α水平。
Objective To investigate the effect of atorvastatin on the levels of IL-1β,IL-6 and TNF-αin the patients with mild cognitive impairment（MCI）and Alzheimer＇s disease（AD）.Methods Sixty patients with MCI were equally randomized into two groups of A1 and A2.Sixty patients with AD were equally randomized into two groups of B1 and B2.Groups of A1 and B1 were treated with oral nimodipine 20 mg,while groups of A2 and B2 were treated with oral nimodipine 20 mg plus atorvastatin 20 mg.The levels of IL-1β,IL-6 and TNF-αin cerebrospinal fluid and blood were detected before and after treatment for 6 months and the relationship among IL-1β,IL-6 and TNF-α were analyzed.Results Six months after treatment,the levels of IL-1β,IL-6 and TNF-αin the four groups were all lower than those before（P〈0.05）,which were lower in groups of A2 and B2 than those in groups of A1 and B1,respectively（P〈0.05）.Besides,the levels of IL-1β,IL-6 and TNF-αin group B2 were lower than those in group A2（P〈0.05）.There was no obvious correlation among IL-1β,IL-6 and TNF-αin the patients with MCI（P〉0.05）,while IL-1β was positively correlated with TNF-αin the patients with AD（r=0.427,P〈0.05）.Conclusion Atorvastatin can significantly reduce the levels of IL-1β,IL-6 and TNF-αin the patients with MCI and AD.
作者
韩健
尹琪华
方央
寿卫清
张聪聪
HAN Jian, YIN Qihua, FANG Yang, et al(Department of Neurology, City Hospital of Shaoxing , Shaoxing 312000, CHIN)
出处
《江苏医药》
CAS
2018年第3期279-281,共3页
Jiangsu Medical Journal
基金
2016绍兴市卫生计划科技计划青年科技项目(2016QN005)
